Jiangsu Aidea Pharmaceutical announced that in order to meet the needs of the follow-up research and development of human-derived protein, the company intends to purchase human-derived protein active pharmaceutical ingredient from Nanjing Nile Pharmaceutical Co., Ltd., and sign relevant agreements for the sale of human-derived protein crude materials and other raw and auxiliary materials and packaging with them. The Board of Directors authorized the management to sign relevant agreements within the limit of no more than RMB 3 million. The authorization period is valid for 12 months from the date of approval by the Board of Directors.